Gastro Esophageal Reflux Clinical Trial
Official title:
Management of Dental Erosion in Patients With Gastroesophageal Reflux Disease With Biomimetic Hydroxyapatite Toothpaste
Verified date | February 2024 |
Source | University of Pavia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the present study is to evaluate dental erosion in patients with gastroesophageal reflux disease (GERD). Patients consenting to participate to the study will undergo periodontal evaluation at the baseline. Then, professional dental hygiene will be performed. Patients will be randomly assigned to: - Trial group: home oral hygiene with Biorepair Total Protection + Biorepair Shock Treatment twice a day - Control group: home oral hygiene with Biorepair Total Protection Patients will be evaluated after 1, 3 and 6 months from baseline.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | May 20, 2024 |
Est. primary completion date | May 17, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - patients with dental erosion - no proton pumps before pH examination Exclusion Criteria: - no dental erosion - neurological and psychiatric diseases; - pregnant and/or breastfeeding women; - patients with poor compliance. |
Country | Name | City | State |
---|---|---|---|
Italy | Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia | Pavia | Lombardy |
Lead Sponsor | Collaborator |
---|---|
University of Pavia |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of BEWE (Basic Erosive Wear Examination) | Scoring criteria (Barlet et al., 2008):
0: no erosive tooth wear; 1: initial loss of surface texture; 2: distinct defect, hard tissue loss < 50% of the surface area; 3: hard tissue loss = 50% of the surface area. IntactTooth smartphone application will be used to calculate this index. |
Study begin, 1, 3 and 6 months after the baseline | |
Primary | Change in Schiff Air Index - Dental sensitivity test | Scoring criteria:
0: the subject did not respond to air blasting; the subject responded to air blasting; the subject responded to air blasting and requested discontinuation; the subject responded to air blasting, requested discontinuation and considered the stimulus to be painful. |
Study begin, 1, 3 and 6 months after the baseline | |
Primary | Change in Plaque Index (PI% - O' Leary Index) | Evaluation of the presence of plaque on the 4 surfaces of teeth on the total amount of dental surfaces.
Formula = n ° sites with plaque / total n ° of dental surfaces x100 |
Study begin, 1, 3 and 6 months after the baseline | |
Primary | Change in Bleeding Score (BS - Mombelli et al.) | Scoring criteria:
0: no bleeding isolated visible spots blood forms a confluent red line on the mucosal margin profuse and copious bleeding |
Study begin, 1, 3 and 6 months after the baseline | |
Primary | Laryngopharyngeal pH monitoring pH monitoring | Data was collected wirelessly for 24 hours and then analysed. Length, severity and number of reflux episodes were calculated. The RYAN score was used to evaluate for laryngopharyngeal acid reflux and was calculated for both the upright and supine positions. A RYAN score >9.4 in the upright position or >6.8 in the supine position was considered positive. Patients with a positive RYAN score in either the upright or supine positions were considered positive for laryngopharyngeal acid reflux. | Study begin, 1, 3 and 6 months after the baseline | |
Primary | Erosion risk level | For each sextant, the highest BEWE value will be chosen. A mean of all the sextant values will be performed to calculate erosion risk level.
IntactTooth smartphone application will be used to calculate this index. |
Study begin, 1, 3 and 6 months after the baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06025773 -
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
|
Phase 1 | |
Recruiting |
NCT06280664 -
Efficacy Of Hiatal Closure For GERD
|
||
Recruiting |
NCT05359965 -
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
|
N/A | |
Completed |
NCT04202692 -
Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
|
N/A | |
Active, not recruiting |
NCT03646045 -
Transpyloric Feeding for Prevention of Micro-aspiration
|
||
Recruiting |
NCT06430047 -
Efficacy and Safety of EsoDuo®
|
Phase 4 | |
Completed |
NCT04268719 -
Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
|
||
Active, not recruiting |
NCT04614974 -
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
|
Phase 1/Phase 2 | |
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Terminated |
NCT04028466 -
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
|
Phase 4 | |
Recruiting |
NCT05066594 -
Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
|
||
Completed |
NCT03476265 -
Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility
|
N/A | |
Completed |
NCT03143608 -
GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery
|
N/A | |
Completed |
NCT04436159 -
Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia.
|
N/A | |
Completed |
NCT03258528 -
Effect of Right Lateral Position on Ventilated Preterm Neonates
|
N/A | |
Active, not recruiting |
NCT04500288 -
The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study
|
N/A | |
Completed |
NCT04262648 -
Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns
|
N/A | |
Recruiting |
NCT04846010 -
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03835663 -
The Bacterial Composition of the Stomach in Reflux Disease
|